Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.28 EPS, up 0% or $0 from last year’s $-0.28 per share.

At the moment 2 analysts are watching ChemoCentryx, Inc. (NASDAQ:CCXI), 0 rate it “Buy”, 1 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 2 analysts have a mean target of 0.00 million.

In terms of earnings per share, 1 analyst has a -0.30 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.30 EPS mean target and for the quarter ending Jun-16 there are 2 estimates of -1.15 EPS.

The biggest institutional shareholders in ChemoCentryx, Inc. include Glaxo Group Ltd which owns 7 million shares in the company valued at $55.44 million. Bvf Inc is the second biggest holder with 7 million shares currently valued at 54.09 million whilst Bio-Techne Corp has 6 million shares valued at 47.07 million.

Total shares held by institutions as of the most recent company filings are 39,129,163 with a reported 706,904 bought and 4,167,338 sold. These holdings make up 88.71% of the company’s outstanding shares.

Currently insiders hold 2,400,846 shares in the business which makes up 5.44% of shares. The biggest holder currently is Dr. Thomas J. Schall, PhD who owns 2,148,667 shares (4.87% of those outstanding), whilst Dr. Roger C. Lucas, PhD holds 67,027 (0.15% of shares outstanding) and Dr. Petrus (Pirow) Bekker, M.D.,PhD holds 53,594 (0.12% of shares outstanding).

The stock increased 6.42% or $0.21 during the last trading session, hitting $5.24. ChemoCentryx, Inc. (NASDAQ:CCXI) has fallen 19.47% over the past 6 months and is downtrending.